Information Provided By: 
Fly News Breaks for June 4, 2018
TGTX
Jun 4, 2018 | 11:26 EDT
H.C. Wainwright analyst Edward White said he believes TG Therapeutics' poster presentation at ASCO further supports his view that umbralisib is a differentiated oral PI3K delta inhibitor. White, who notes that the Phase 3 UNITY-CLL trial remains on target for ORR data this summer, keeps a Buy rating and $38 price target on TG Therapeutics shares.
News For TGTX From the Last 2 Days
There are no results for your query TGTX
